Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...
Why cutting back on salt is important—but going too low may disrupt blood pressure, electrolytes and overall health.
Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback